

CURRICULUM VITAE

Name: Alice Rossi

Date of birth: 30-12-1992

Place of Birth: Alzano Lombardo, Bergamo, Italy

Citizenship: Italian

Italian Medical Council registration number: 07705, OMCEO Bergamo

Email: rossi.alice.bg@gmail.com

Work Experience:

- From 17 January 2024 - ongoing: Sub-Investigator at Clinical Trial Unit, Centro Ricerche Cliniche (CRC), Verona, Italy
- From 01 October 2024 - ongoing: PhD Student, "Inflammation, Immunity and Cancer", University of Verona, Italy
- From 20 December 2023 – 30 September 2024: Research project at Dipartimento di Ingegneria per la Medicina di Innovazione (DIMI), University of Verona "PNC-E3-2022-23683266-HUB INNOVA Diagnostica avanzata (HLS-DA)"
- July 2023 – December 2023: Medical Training at Phase 1 Unit (Director Dr Elena Garraza), Vall d'Hebron Institute Oncology VHIO (Director Dr Josep Tabernero), Barcelona, Spain
- November 2021-April 2022: Medical Oncology Residency, extra-University period in Unit of Medical Oncology, Vicenza Hospital – Director Dr Giuseppe Aprile
- March - April 2020: Medical Service in Covid-19 Unit (Medical Unit and Subintensive Care Unit), Policlinico G.B. Rossi, Borgo Roma, Verona, Italy
- November 2018 – November 2023: Medical Oncology Residency, University of Verona, Italy – Director: Prof. Michele Milella, Prof. Sara Pilotto
- April 2018 - June 2019: Primary Care Doctor, ASST Bergamo Est, Italy

Education and Training:

- Jul 11, 2025: CH GCP E6 R3 Investigator Site Training
- March 15-16, 2024: ALS training - Advanced life support training
- May 15, 2024: ICH-GCP training
- November 17, 2023: Postgraduate Specialization in Medical Oncology – University of Verona, Italy (70/70 cum Laude). Experimental thesis: "Application of a translational model to study the efficacy and the resistance mechanisms in patients treated with targeted therapy at the Vall d'Hebron Institute of Oncology (VHIO)"
- June 17-23, 2023: MCCR (EORTC-ESMO-AACR) Workshop on Methods in Clinical Cancer Research
- May 13, 2022 ICH-GCP training
- February 17-18, 2020 ALS training - Advanced life support training
- March 1, 2018: member of General Medical Council of Bergamo (Italy), reference number 07705
- February 15, 2018: Italian Medical License Exam (IMLE) – University of Pavia, Italy
- July 10, 2017: Master Degree in Medicine and Surgery (Harvey Course) – University of Pavia, Italy (110/110 cum Laude). Experimental thesis: "Pulmonary Artery Sarcoma: a Single-Institution Experience of a multimodal therapeutic approach to a rare malignant tumor"
- October 2015 - March 2018: traineeship as Medical Student – Department of Medical Oncology, IRCCS San Matteo, University of Pavia (Italy) – Director Prof Paolo Pedrazzoli
- 2011: High School Diploma in Scientific Studies

Clinical Research Activities:

- 2024-2025 Sub Investigator: Study of Zanzalitinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (STELLAR-305)
- 2024-2025 Sub Investigator: Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors
- 2024-2025 Sub Investigator: A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200603 (anti-BTLA antibody) as a Single Agent and in Combination with Tislelizumab (anti-PD-1 antibody) in Adult Patients with Advanced Solid Tumors
- 2024-2025 Sub Investigator: A Phase I, Multicenter, Open-label, First-in Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors
- 2024-2025 Sub Investigator: 2138-CL-0101 / Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

- 2024 Sub Investigator: An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)
- 2024-2025 Sub Investigator: A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors
- 2024-2025 Sub Investigator: IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab, Standard of Care Chemotherapy, or TransCon TLR7/8 Agonist, or in Combination with Pembrolizumab and Standard of Care Chemotherapy, in Adult Participants with Locally Advanced or Metastatic Solid Tumor Malignancies
- 2024-2025 Sub Investigator: A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
- 2024 Sub Investigator: A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies
- 2022-2023 Sub Investigator: A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined With Nivolumab Versus Placebo With Nivolumab in Patients With Unresectable or Metastatic Melanoma Not Previously Treated With PD-1 or PD-L1 Inhibitors.
- 2022-2023 Sub Investigator: A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor(pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2 α Related Genetic Alterations
- 2021 Sub-Investigator: A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive ProstateCancer (mHSPC) (KEYNOTE-991).
- 2021 Sub Investigator: A Phase 3, Randomized, Double-blind Trial of Pembrolizumab(MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
- 2021 Sub Investigator: An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line Treatment inParticipants with Advanced Renal Cell Carcinoma Who Have Progressed After 1 Prior Anti-PD-1/L1 Combination Regimen.
- 2021 Sub Investigator: A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone forAdjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA).
- 2020 Sub-investigator: A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions.
- 2020 Sub-investigator: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction(KEYNOTE-676).
- 2020 Sub-investigator: Assessment of bone response after LHRH-A and Enzalutamide plus minus Zoledronic Acid in prostate cancer patients with hormonesensitive metastatic bone disease: a prospective, phase II, randomized, multicenterstudy (Bonenza trial).
- 2020 Sub-investigator: A Phase 3, Randomized, Double-blind Study to Compare theEfficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011).
- 2020 Sub-investigator: An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That HasProgressed After Prior PD-1/L1 and VEGF-Targeted Therapies.
- 2020 Sub-investigator: Phase II study of Avelumab plus intermittent Axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study)
- 2020 Sub-investigator: A phase I Dose Esclation Study of NMS-03305293 in AdultPatients with Selected Advanced/Metastatic Solid Tumors.

Publications:

- **Rossi Alice**, and Alberto Hernando-Calvo. "Molecular Characterization of Salivary Gland Cancer and Treatment Implications." *Critical Issues in Head and Neck Oncology: Key Concepts from the Ninth THNO Meeting*. Cham: Springer Nature Switzerland, 2025
- **Rossi, A.**, Zampiva, I., Sperduti, I., Conciatori, F., Bazzichetto, C., Nocini, R., & Milella, M. (2024). Preserving momentum on next-generation sequencing for head and neck squamous cell carcinoma. *Annals of Oncology*, 35(10), 919-921.
- **Rossi, A.**, Zacchi, F., Reni, A., Rota, M., Palmerio, S., Menis, J., ... & Milella, M. (2024). Progresses and Pitfalls of Epigenetics in Solid Tumors Clinical Trials. *International Journal of Molecular Sciences*, 25(21), 11740.
- Borghesani, M., Reni, A., Lauricella, E., **Rossi, A.**, Moscarda, V., Trevisani, E., ... & Cingarlini, S. (2024). Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. *Journal of the National Comprehensive Cancer Network*, 1(aop), 1-8.
- Trentin L, Basile D, Lazzari E, Fietta E, **Rossi A**, Graziani F, Cappetta A, Simionato F, D'Amore E, Perbellini O, Aprile G. Implementation of a MSRE ddPCR method for the detection of methylated *WIF1* and *NPY* genes in colorectal cancer patients. Tumori. 2024 Aug 5:3008916241261675. doi: 10.1177/03008916241261675. Epub ahead of print. PMID: 39101541.
- Hernando-Calvo, A., **Rossi, A.**, Vieito, M., Voest, E., & Garraalda, E. (2024). Agnostic drug development revisited. *Cancer Treatment Reviews*, 102747. doi: <https://doi.org/10.1016/j.ctrv.2024.102747>
- Pacelli C, **Rossi A**, Milella M, Colombo T, Le Pera L. RNA-Based Strategies for Cancer Therapy: In Silico Design and Evaluation of ASOs for Targeted Exon Skipping. *International Journal of Molecular Sciences*. 2023; 24(19):14862. <https://doi.org/10.3390/ijms241914862>
- D. Tregnago, S. Zuliani, I. Zampiva, M. Casali, A. Cavaliere, A. Fumagalli, S. Merler, S.T. Riva, **A. Rossi**, F. Zacchi, E. Zaninotto, A. Caldart, S. Casalino, M. Gaule, D. Kadrija, M. Mongillo, M. Rimondini, L. Del Piccolo, M. Milella, S. Pilotto "Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic". *Eur J Cancer*. 2020 May; 135:159-169.
- M. Ottaviano, M. Curvietto, P. Rescigno, M. Tortora, G. Palmieri, D. Giannarelli, M. Aieta, P. Assalone, L. Attademo, A. Avallone, F. Bloise, D. Bosso, V. Borzillo, G. Buono, G. Calderoni, F. Caputo, G. Carteni, D. Cavallero, A. Cavo, F. Ciardiello, R. Conca, V. Conteduca, S. De Falco, M. De Felice, M. De Laurentiis, P. De Placido, S. De Placido, I. De Santo, A. De Stefano, C. M. Della Corte, R. Di Franco, V. Di Lauro, A. Fabbrocini, P. Federico, L. Festino, P. Giordano, M. Giuliano, C. Gridelli, A.M. Grimaldi, M. Lia, A. L. Marretta, V. Massa, A. Mennitto, S. Merler, V. Merz, C. Messina, M. Messina, M. Milano, Marco Minisini, V. Montesarchio, A. Morabito, F. Morgillo, B. Mucci, L. Nappi, F. Napolitano, I. Paciolla, M. Pagliuca, G. Palmieri, S. Parola, S. Pepe, A. Petrillo, F. Piantedosi, L. Piccin, F. Picozzi, E. Pietrolungo, S. Pignata, V. Prati, V. Riccio, M. Rosanova, **A. Rossi**, A. Russo, M. Salati, G. Santabarbara, A. Sbrana, E. Simeone, A. Silvestri, M. Spada, P. Tarantino, P. Taveggia, F. Tomei, V. Tortora, D. Trapani, C. Trojanello, V. Vanella, S. Vari, J. Ventriglia, M.G. Vitale, F. Vitiello, C. Vivaldi, C. vonArx, F. Zacchi, I. Zampiva, A. Zivi, B. Daniele, P.A. Ascierto Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. *Journal for ImmunoTherapy of Cancer* 2020;8:e001154. doi:10.1136/jitc-2020-001154
- Zampiva I, Merler S, Zacchi F, **Rossi A**, Zivi A, Delayed Asymptomatic ICI-Related Colitis in Renal Cancer; *Journal of Clinical and Medical Images*; ISSN: 2640-9615/Volume 5(10): 1-2.
- **Alice R**, Michele B, Claudio L, Andrea M, Sara C (2023) Adult-Onset Metastatic Pancreatic Ganglioneuroblastoma with ALK Gain-of-Function Mutation P.R1275Q Treated with Lorlatinib. *J Clin Stud Med Case Rep* 10: 0150.
- Elena Trevisani, Michele Borghesani, Anna Reni, Irene Torresan, **Alice Rossi**, Silvia Nicolini, Michele Milella, Fulvia Mazzaferri, Isacco Ferrarini, Alice Parisi and Sara Cingarlini (2023). Unusual Presentations for EBV and HHV8 Co-Infections: A Case Report and Review of Literature. *Journal of Clinical Case Studies Reviews & Reports*. SRC/JCCSR-227. DOI: doi.org/10.47363/JCCSR/2023 (5), 258, 2-6.

Abstract and Posters:

- **Rossi A.** et al, Tissue-based Next Generation Sequencing (NGS) for Patients with Advanced Solid Tumors: the experience of Verona University Hospital. Poster Associazione Italiana di Oncologia Medica (AIOM) 2024 Congress.
- Puerto, D. G., **Rossi, A.**, Calvo, A. H., Hermida, J. U., Gómez, M., Matito, J., ... & Vivancos, A. (2024). 127P Clinical utility of circulating tumor DNA (ctDNA) next generation sequencing (NGS) to inform treatment decisions for patients (pts) with advanced solid tumors. *Annals of Oncology*, 35, S265-S266.
- **Rossi A.**, Cingarlini S., Borghesani M., Moscarda V., Torresan I., Trevisani E., Landoni L., de Robertis R., Luchini C., Mafficini A., Milella M. and Scarpa A., NGS data collection in high-grade (HG) pancreatic NENs at University Hospital of Verona. Abstract ENETS 2023, <https://onlinelibrary.wiley.com/doi/pdf/10.1111/jne.13265>, pag. 32.
- Elena Trevisani; Anna Reni; Irene Torresan; **Alice Rossi**; Michele Borghesani; Silvia Nicolini; Claudio Luchini; Luca Landoni; Davide Melisi; Aldo Scarpa; Michele Milella; Andrea Mafficini; Sara Cingarlini. Abstract 3814: Molecular background conditioning by temozolomide in neuroendocrine tumors. *Cancer Res* (2024) 84

(6_Supplement): 3814. <https://doi.org/10.1158/1538-7445.AM2024-3814>.

- **Alice Rossi**, Elena Trevisani, Silvia Riva, Anna Reni, Andrea Mafficini, Claudio Luchini, Federico Sganzerla, Michela Piacentini, Luca Pasqualin, Michele Rota, Barbara Avesani, Davide Melisi, Luca Tondulli, Alessandra Auriemma, Jessica Menis, Sara Cingarlini, Francesca Mansa Atsina, Rita T. Lawlor, Aldo Scarpa, Michele Milella. From seed to harvest: 18-month experience of molecular tumor board (MTB)-based precision oncology practice at the Verona University Hospital. DOI: 10.1200/JCO.2023.41.16_suppl.e15065 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) e15065-e15065.
- Viola Moscarda, Elena Trevisani, Anna Reni, **Alice Rossi**, Irene Torresan, Michele Borghesani, Silvia Nicolini, Lavinia Benini, Sara Cingarlini, Davide Melisi, Andrea Mafficini, Claudio Luchini, Luca Landoni, Aldo Scarpa, Michele Milella. Precision medicine applied to rare malignancies: A single-center experience at University Hospital of Verona. DOI: 10.1200/JCO.2023.41.16_suppl.e16296 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) e16296-e16296.
- Atsina, F. M., **Rossi, A.**, Bolcato, I., Fraccaroli, R., Alberti, C., Scardoni, L., ... & Milella, M. (2023). Temporal trends of atypical drug access at an academic oncology unit: The Verona University Hospital experience. JCO 41, e13651-e13651(2023). DOI:10.1200/JCO.2023.41.16_suppl.e13651
- D. Tregnago, S. Zuliani, I. Zampiva, M. Casali, A. Cavaliere, A. Fumagalli, S. Merler, S.T. Riva, A. **Rossi**, F. Zacchi, E. Zaninotto, A. Caldart, S. Casalino, M. Gaule, D. Kadrija, M. Mongillo, M. Rimondini, L. Del Piccolo, M. Milella, S. Pilotto. Oncological patients' perception of infection risks and level of acceptance of protective measures during SARS-CoV-2 pandemic Annals of Oncology 31 (Supplement 4) s1003. 2020;

Educational activities

- Co-supervisor of student's thesis (dr Francesco Bovo) in Medicine and Surgery, University of Verona, Italy

Membership:

- ESMO Member (2019 – ongoing)
- AIOM Member (2023 – ongoing)
- ENETS Member (2023)
- ITANET Member (2023)

Languages spoken:

- Italian: mother tongue
- English: fluent
- Spanish: good oral and written communication skills
- German: basic oral and written communication skills

I authorize the processing of my data according to the applicable local regulation about data protection and any further amendments (D. Lgs 196/2003 as amended by D Lgs 101/2018 and GDPR – General Data Protection Regulation n°2016/679).

Verona, 11/Oct/2025

